We serve Chemical Name:Rhodium CAS:7440-16-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Rhodium
CAS.NO:7440-16-6
Synonyms:RhodiuM Rh/C;Rhodium;rh-945;RH;rhodium atom;EINECS 233-397-6;ESCAT 3401;RHODIUM BLACK;RHODIUM METAL;MFCD00011201
Molecular Formula:Rh
Molecular Weight:102.906
HS Code:7110310000
Physical and Chemical Properties:
Melting point:1966 °C(lit.)
Boiling point:3727 °C(lit.)
Density:1.41 g/mL at 25 °C
Index of Refraction:
PSA:
Exact Mass:102.905502
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3089 4.1/PG 2
Packing Group:III
Contact us for information like RhodiuM Rh/C chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00011201 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,ESCAT 3401 Use and application,RHODIUM BLACK technical grade,usp/ep/jp grade.
Related News: AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment. Rhodium manufacturer Optimize the reaction and improve the production process to reduce the production cost. At the same time, strengthen the determination and analysis of impurities to improve product quality. Rhodium supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician��s Choice plus Best Supportive Care. Rhodium vendor According to the 2013-2018 New Drug Review Summary report, from 2013 to 2018, new drug applications have shown a year-on-year growth trend. In 2018, domestically produced Class 1 new drugs have declared 225 varieties, the highest in 10 years. Rhodium factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.
